Multiple Myeloma Forums - Home
Last Updated on Saturday, 26 December 2009 15:53 Written by Administrator Tuesday, 14 April 2009 04:49
This site was started to promote communication among the Myeloma community. Whether you're new to Myeloma or a seasoned veteran we encourage you to take a moment to register and engage the community.
This is a friendly community where you can ask or say anything Myeloma related without the fear of being ridiculed or banned. Active members in this community should be able to walk away with a wealth of information and know they are making the best decisions possible.
By sharing information on here we can learn about: The best treatment options, clinical trials, dieting, pain management, doctors, organizations, events, news, and so much more. This community should bring people together from every corner of the world and allow each of you to know what treatment options are offered outside of your country as well.
Knowledge is power!
Andy
If your new to this website please check out the below links first:
New User Registration
Browse the forums
Watch educational videos about Multiple Myeloma
Quick how to post to the forums video
How to resolve login issues
Multiple Myeloma Facts
Last Updated on Saturday, 06 June 2009 18:07 Written by Administrator Sunday, 19 April 2009 17:00
What is Myeloma?
Myeloma, or multiple myeloma, is cancer of a certain type of blood cell called a plasma cell. It begins in the bone marrow, where blood cells are made. Bone marrow is found in the soft, spongy center of certain bones.
In adults, marrow usually is active only in the skull, shoulders, spine, ribs, pelvis and hips. (It’s not active lower in the arms, hands, legs or feet.) Myeloma can affect any bones where marrow is active.
Healthy bone marrow produces the three major types of blood cells our bodies need.
- White blood cells fight infection.
- Red blood cells carry oxygen.
- Platelets make the blood clot and stop bleeding.
Myeloma affects one type of white blood cell, called a plasma cell, that’s part of your immune system. Normally when bacteria or viruses enter your body, white blood cells called B lymphocytes, or B cells, turn into plasma cells to fight these germs. The plasma cells make antibodies to destroy the specific type of infection you have.

In myeloma, plasma cells don’t reproduce normally, and they can’t perform their normal immune duties. The cancerous plasma cells, also called myeloma cells, divide and grow out of control, building up in the marrow and crowding out other healthy blood cells. This can increase your risk of infection, anemia (shortage of oxygen-carrying red blood cells) and blood-clotting problems.
Pesticides Linked to Precancerous Blood Disorder
Last Updated on Wednesday, 09 December 2009 01:59 Written by Administrator Wednesday, 09 December 2009 01:53
Individuals who apply pesticides to crops are twice as likely as the general population to develop a precancerous blood disorder called MGUS (monoclonal gammopathy of undetermined significance), which can lead to multiple myeloma, according to the results of a study published in Blood.Multiple myeloma is a cancer of the blood that affects the plasma cells, which are an important part of the immune system that produce antibodies to help fight infection and disease. Multiple myeloma is characterized by an excess production of abnormal plasma cells. Symptoms include increased risk of bacterial infections and impaired immune responses. Almost all patients with multiple myeloma experience the plasma disorder MGUS before developing myeloma.

Previous studies have indicated that pesticides may be associated with an increased risk of multiple myeloma. This more recent study included a cohort of 678 men ages 30-94 from the Agricultural Health Study (which included over 57,000 subjects). The men work as pesticide applicators in North Carolina and Iowa and were enrolled in the study between 1993 and 1997. They provided blood samples that were analyzed for MGUS and then compared with samples from 9,469 men from the general population in Minnesota.
Onyx drug shows promise in multiple myeloma study
Last Updated on Tuesday, 22 December 2009 22:13 Written by Administrator Wednesday, 09 December 2009 01:46
NEW YORK, Dec 7 (Reuters) - An experimental cancer drug recently acquired by Onyx Pharmaceuticals Inc showed promising response rates in patients with relapsed and/or refractory multiple myeloma, according to interim data from a pair of small mid-stage trials.
The studies, presented on Monday at the American Society of Hematology (ASH) meeting in New Orleans, tested carfilzomib given intravenously every 28 days in 73 patients who had not previously been treated with Takeda Pharmaceuticals' Velcade, and in 33 others following treatment with Velcade.
![]()
"These interim results suggest that carfilzomib could benefit patients with multiple myeloma who are no longer responding to current therapies," Dr. David Siegel, co-investigator of the studies, said in a statement.
Onyx acquired carfilzomib with its purchase last month of Proteolix Inc, saying the drug for multiple myeloma, a blood cancer, has the potential for accelerated U.S. approval in 2011.
New Velcade®-melphalan Transplant Regimen for Multiple Myeloma
Written by Administrator Wednesday, 09 December 2009 01:38
Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.
![]()
Velcade is the first in a new class of anticancer agents known as proteasome inhibitors and is being evaluated in clinical trials for the treatment of patients with refractory hematologic malignancies, especially multiple myeloma. As a single agent, Velcade has a response rate of approximately 30%, and 4-5% of these responses are complete. A recent study has also shown that Velcade produces a 90% response rate in patients with newly diagnosed multiple myeloma.
Read full article at publishers website
Cancercare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs
Last Updated on Tuesday, 25 August 2009 03:27 Written by Administrator Tuesday, 25 August 2009 03:20

"Door to Door" initiative offers individual grants to patients to help defray transportation costs to and from medical care.
New York, NY, July 20, 2009— CancerCare announced today the launch of the "Door to Door" program for patients with multiple myeloma. CancerCare's program will provide individual grants of up to $600 annually to multiple myeloma patients for covering transportation costs such as gasoline, parking and tolls, and taxi, bus or train fare to and from their medical care.
The program is funded in part by a generous grant from Millennium: The Takeda Oncology Company. CancerCare is a national non-profit organization based in New York City that provides free support services to people affected by cancer.
Multiple myeloma is a cancer of the bone marrow that is diagnosed in approximately 20,000 people annually in the U.S. Advances in the treatment of this cancer have dramatically increased patients' life expectancy (an estimated 60,000 people in the U.S. are now living with multiple myeloma) and consequently lengthened the duration of treatment.
"Because of the nature of their therapies and the disease itself, many multiple myeloma patients may be required to visit their doctors several times a week over many months. Particularly for patients on a fixed income, these travel expenses add up and create a financial burden that may prevent them from keeping up with their health care," noted Diane Blum, executive director of CancerCare. "The Door to Door program will provide much-needed relief to this patient population, and we are grateful for Millennium's support."
Founded in 1944, CancerCare has a long track record of providing financial assistance to people facing cancer; it is a cornerstone of its direct support services to help people cope with the emotional and practical issues of a cancer diagnosis. During fiscal year 2009, CancerCare provided over $4.2 million in grants to more than 24,000 people with cancer to cover treatment-related costs like transportation, child care and medications for side effects.
Last year CancerCare launched a separate foundation to help cancer patients cover the cost of their health insurance co-payments for certain types of treatments. To date, the CancerCare Co-Payment Assistance Foundation has assisted thousands of people undergoing cancer treatments with grants of up to $10,000.
To receive a Door to Door transportation grant, patients must meet certain eligibility criteria and complete an application form. A sample patient application form along with a physician verification form may be viewed online. To apply, call 1-800-813-HOPE (4673).
For more information about multiple myeloma, read CancerCare's free Connect booklet, Advances in the Treatment of Multiple Myeloma.
More Articles...
Page 1 of 6
«StartPrev123456NextEnd»Users Online
- lnesseler
Recent Forum Topics
- 02/08/2010 23:01 Greetings from Canada! (sunshine)
- 02/08/2010 21:19 Greetings from Canada! (The Cancer Diaries)
- 02/08/2010 14:52 Dad with multiple myeloma - lots of questions! (The Cancer Diaries)
- 02/03/2010 19:42 M spike (bigjohn707)
- 02/03/2010 13:11 Working & Treatments - What's Possible/Impossible? (emoore)
- 02/01/2010 02:44 After radiation question's (Supersid)
- 01/31/2010 21:18 Revlimid question (zerofeel)
- 01/28/2010 23:31 M spike (sunshine)
- 01/28/2010 09:02 Revlimid question (royjulius)
- 01/27/2010 21:03 M spike (bigjohn707)
- 01/27/2010 20:13 Well Met (sunshine)
- 01/27/2010 20:11 farctures and slow bone healing? (sunshine)
- 01/27/2010 19:54 After radiation question's (sunshine)
- 01/27/2010 19:49 Hi.New member,new diagnosis (sunshine)
- 01/27/2010 19:39 Second opinions (sunshine)
Tag Cloud
Search Articles
Polls
Polls
Myeloma News
- Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients...
- Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients...
- HEALTH (Bucks County Courier Times)
- At your service (Daytona Beach News-Journal)
- Food Allergy Support Group meets Mondays in Westlake (The Sun Post-Herald)
Medworm
- Latest issue of Myeloma Today is on the web
- 2010 Brian D. Novis Research Grant Recipients Announced
- Issues of importance to patients are getting lost in partisan battles in Congress. Get involved!
- Issues of immediate importance to patients are getting lost in partisan battles in Congress. Get...
- New Tip Card for Mozobil (plerixafor injection)
- Amy Weiss, entertainment industry exec, joins IMF Board of Directors
- IMF signs letter of support for Clinical Trials Coverage Provision in Health Reform Legislation
- New NCI Course - "Including Clinical Trials in Your Practice"
Myeloma Beacon
- Beacon NewsFlashes – February 5, 2010
- Addition Of Defibrotide To Melphalan-Prednisone-Thalidomide Combination Produces Fewer Side Effects In Multiple Myeloma Patients
- Velcade-Doxil-Dexamethasone Regimen Followed By Post-Transplant Revlimid May Be A Highly Effective Treatment For Newly Diagnosed...
- Personal Perspective: Former Football Star And Young Father “Dominates” Cancer With Optimism, Information, And Support
- Beacon NewsFlashes – January 29, 2009
- Post-Transplant Revlimid Therapy Increases Complete Response Rates In Multiple Myeloma Patients, Study Finds (ASH 2009)
- Despite Side Effects, High-Dose Melphalan Remains The Most Effective Dosage In Preparation For Stem Cell...
- Velcade Induction and Maintenance Combinations Are Highly Effective In Elderly Multiple Myeloma Patients, Study Finds...
- Beacon NewsFlashes – January 25, 2010
- Thought Leader Perspective: Dr. Robert Kyle On Myeloma Treatments Requiring Further Study
Archives by month
Visitors Counter






![]() | Today | 263 |
![]() | Yesterday | 697 |
![]() | This week | 1653 |
![]() | Last week | 4905 |
![]() | This month | 5872 |
![]() | Last Month | 17504 |
![]() | All | 80488 |
Your IP: 38.107.191.101
,
Now is: 2010-02-09 09:02








